These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1420751)

  • 21. Ranitidine, 150 mg three times a day, in the treatment of reflux oesophagitis. A placebo-controlled, double-blind study.
    Lehtola J; Niemelä S; Martikainen J; Krekelä I
    Scand J Gastroenterol; 1986 Mar; 21(2):175-80. PubMed ID: 3520796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An evaluation of increasing doses of ranitidine for treatment of heartburn.
    Pappa KA; Buaron K; Payne JE; Sirgo MA; Giefer EE
    Aliment Pharmacol Ther; 1999 Apr; 13(4):475-81. PubMed ID: 10215731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of erosive oesophagitis relapse with pantoprazole.
    Richter JE; Fraga P; Mack M; Sabesin SM; Bochenek W;
    Aliment Pharmacol Ther; 2004 Sep; 20(5):567-75. PubMed ID: 15339328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of ranitidine, given t.d.s., on intragastric and oesophageal pH in patients with gastrooesophageal reflux.
    Russell J; Orr WC; Wilson T; Finn AL
    Aliment Pharmacol Ther; 1991 Dec; 5(6):621-30. PubMed ID: 1782305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of combined therapy with ranitidine and pirenzepine in the treatment of reflux oesophagitis.
    Londong W; Phillips J; Johnson NJ; Wood JR
    Aliment Pharmacol Ther; 1992 Oct; 6(5):609-18. PubMed ID: 1420752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.
    Klinkenberg-Knol EC; Jansen JM; Festen HP; Meuwissen SG; Lamers CB
    Lancet; 1987 Feb; 1(8529):349-51. PubMed ID: 2880161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
    Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
    Metz DC; Howden CW; Perez MC; Larsen L; O'Neil J; Atkinson SN
    Aliment Pharmacol Ther; 2009 Apr; 29(7):742-54. PubMed ID: 19210298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis.
    Simon TJ; Berenson MM; Berlin RG; Snapinn S; Cagliola A
    Aliment Pharmacol Ther; 1994 Feb; 8(1):71-9. PubMed ID: 8186349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
    Laine L; Katz PO; Johnson DA; Ibegbu I; Goldstein MJ; Chou C; Rossiter G; Lu Y
    Aliment Pharmacol Ther; 2011 Jan; 33(2):203-12. PubMed ID: 21114792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study.
    Inauen W; Emde C; Weber B; Armstrong D; Bettschen HU; Huber T; Scheurer U; Blum AL; Halter F; Merki HS
    Gut; 1993 Aug; 34(8):1025-31. PubMed ID: 8174947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy.
    Larson JD; Patatanian E; Miner PB; Rayburn WF; Robinson MG
    Obstet Gynecol; 1997 Jul; 90(1):83-7. PubMed ID: 9207819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis.
    Katz PO; Castell DO; Levine D
    Aliment Pharmacol Ther; 2003 Nov; 18(9):875-82. PubMed ID: 14616151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute treatment of reflux oesophagitis: a multicentre study to compare 150 mg ranitidine twice daily with 300 mg ranitidine at bedtime.
    Halvorsen L; Lee FI; Wesdorp IC; Johnson NJ; Mills JG; Wood JR
    Aliment Pharmacol Ther; 1989 Apr; 3(2):171-81. PubMed ID: 2491468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study.
    Sontag SJ; Hirschowitz BI; Holt S; Robinson MG; Behar J; Berenson MM; McCullough A; Ippoliti AF; Richter JE; Ahtaridis G
    Gastroenterology; 1992 Jan; 102(1):109-18. PubMed ID: 1727744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study.
    Rush DR; Stelmach WJ; Young TL; Kirchdoerfer LJ; Scott-Lennox J; Holverson HE; Sabesin SM; Nicholas TA
    J Fam Pract; 1995 Aug; 41(2):126-36. PubMed ID: 7636452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine.
    Bianchi Porro G; Pace F; Peracchia A; Bonavina L; Vigneri S; Scialabba A; Franceschi M
    J Clin Gastroenterol; 1992 Oct; 15(3):192-8. PubMed ID: 1479161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial.
    Havelund T; Laursen LS; Skoubo-Kristensen E; Andersen BN; Pedersen SA; Jensen KB; Fenger C; Hanberg-Sørensen F; Lauritsen K
    Br Med J (Clin Res Ed); 1988 Jan; 296(6615):89-92. PubMed ID: 3122967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
    Feldman M; Harford WV; Fisher RS; Sampliner RE; Murray SB; Greski-Rose PA; Jennings DE
    Am J Gastroenterol; 1993 Aug; 88(8):1212-7. PubMed ID: 8101695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s.
    Johnson NJ; Boyd EJ; Mills JG; Wood JR
    Aliment Pharmacol Ther; 1989 Jun; 3(3):259-66. PubMed ID: 2520621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.